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α-synuclein is a protein that plays important roles in cognitive function in the normal brain, although its exact role
is not fully understood. However, current studies reveal that defects in α-synuclein function could contribute to
various neurodegenerative disorders, such as Parkinson’s disease (PD), a disease with symptomatic progression of
deterioration in motor and cognitive function. Recent studies show that the level of α -synuclein in cerebrospinal
fluid (CSF) is highly correlated with speed of cognitive decline, suggesting a potential role of α-synuclein in cognitive
function. In this mini review, we will be focus on literatures of α-synuclein in cognitive function in the non-diseased
brain, as well as the impact that defective α-synuclein has on cognition in disease brain. This will be accomplished
by assessing the effects of soluble α-synuclein, α-synuclein oligomers, and extracellular α-synuclein transport,
on neurodegeneration.
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α-synuclein aggregates, which interact with various hor-
mones, neurotransmitters, and other macromolecules,
are involved in the pathogenesis of many neurodegenera-
tive diseases. There has been an overall consensus that the
general cause of many neurodegenerative dementias is
due to the improper folding of specific proteins and their
accumulation into aggregate species [1-3]. It is well known
that α-synuclein plays significant roles in PD. However, it
is still unclear when and how these α-synuclein oligomers
occur in pathogenesis of PD. Alpha-synuclein localizes to
Lewy Bodies, a major pathological marker of PD, and can
be detected in various brain regions and nerve nuclei de-
pending on different stages of the disease. For instance,
α-synuclein is increased in the dorsal motor nucleus of
the vagus nerve, the locus ceruleus, and the substantia
nigra during the early phase of PD and in the cerebral cor-
tical areas of advanced PD, ultimately affecting motor
skills and causing a decline in cognitive function [1,4,5]
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unless otherwise stated.threonine181), and α-synuclein in CSF have prognostic and
diagnostic potential in early-stage of PD. Although there
are many hypotheses about the role of α-synuclein mecha-
nisms in PD, there is uncertainty on the physiological
function of α-synuclein. In PD brain, there is a correlation
between protein aggregates in the hippocampus and cog-
nitive deficits, such as volume loss in the cornu armonis
(CA2) regions of the hippocampus and related learning
impairment. In addition, PD patients with mild cognitive
impairments also had defects in the prefrontal cortex and
caudate nucleus, suggesting a brain regional atrophy re-
lated dysfunction of cognition in PD [6,7]. An interesting
study that examined the pathology of cortical and striatal
a-synucelin in patients with PD, Parkinson’s disease de-
mentia (PDD), and dementia with Lewy bodies (DLB) and
reported that patients with PDD and DLB had greater
pathology for cortical and striatal α -synuclein than did
patients with PD [8], suggesting a direct association be-
tween α -synuclein and dementia.α-Synuclein under normal physiological conditions
Structure of endogenous α-synuclein in the normal brain
α-Synuclein is a cytosolic neuronal protein from the
structurally related synuclein family of proteins. The
N-terminal membrane binding domain of synuclein pro-
teins possess a highly conserved motif, which consists ofhis is an Open Access article distributed under the terms of the Creative
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teins share a natively unfolded tertiary structure. Unlike
the N-terminus, the C terminus of synuclein proteins is
polar, containing high amounts of charged residues. The
α-Synuclein proteins are highly localized at the presynap-
tic terminals and they have also been expressed in the
nucleus and cytoplasmic regions [9]. In its native form,
α-Synuclein is present as an unfolded monomer with an
approximate size of 14 kDa. When α-Synuclein is bound
to lipid vesicles, it acquires α-helical secondary structures,
creating a folded tetramer of about 58 kDa [10]. Although
extensive molecular studies have been done in vitro,
the structure of α-Synuclein in cells has not been fully
determined.
Functions of α-synuclein in normal physiological conditions
Although α-Synuclein has been implicated in numerous
cellular processes, the exact physiological function of α-
Synuclein remains elusive. However, much research has
identified various mechanisms in which α-synuclein
interacts with neurotransmitters, lipids, carbohydrates,
membrane bound receptors, and other proteins in the
brain. Reported binding targets for α-Synuclein includes,
phospholipase D2 and protein kinase C. The highly con-
served amino-terminal domain of α-Synuclein enables it
to interact with synthetic lipid vesicles and it helps to me-
diate dimerization. In addition, it is known that the polar
C-terminus of α-Synuclein undergoes multiple phosphor-
ylation events, indicating a possible regulatory role of the
C-terminus. In addition, it has been discovered that
α-Synuclein can act as ATP-independent molecular chap-
erons, which helps to prevent accumulation of denatured
proteins [11]. To help determine the normal function
of α-Synuclein, an experiment was carried out using
α-Synuclein deficient mice. Results from the study sup-
ported the theory that α-Synuclein is an activity –dependent
negative regulator of dopamine neurotransmission [12].
To further understand the function of α-synuclein ex-
pression in normal physiological conditions, a study was
conducted using mice with over-expressed α-synuclein. It
was found that overexpression of α-Synuclein protected
against paraquat-induced neurodegeneration, suggesting
that α-synuclein plays a role against toxic insults-induced
neurodegeneration [13]. Thus, the predominant normal
functions of α-Synuclein in synaptic vesicle trafficking and
neurotransmission may be involved.
Current research proposes that α-Synuclein has an
indirect role in the soluble N-ethylmaleimide-sensitive
factor attachment protein receptor (SNARE) proteins,
which are involved in vesicle fusion. Under physiological
conditions, α-Synuclein initiates the assembly of the
SNARE machinery, where it is thought to play a role in
the release of neurotransmitters [9]. Furthermore, it
has been demonstrated that α-Synuclein inhibits SNARE-mediated vesicle fusion by binding to the lipid bilayer
membrane, followed by an indirect interaction between
α-Synuclein and the SNARE proteins. The crucial in-
volvement of α-Synuclein in modulating SNARE proteins
is supported by an experimental design, which provided
insight on the mechanistic action of α-Synuclein in regu-
lating neurotransmission. The study utilized a lipid regula-
tor, arachidonic acid, to stimulate the formation of the
SNARE complex and enhance the ability of α-Synuclein to
control exocytosis both in vitro and in vivo. Α-Synuclein
was able to sequester arachidonic acid and block the acti-
vation of SNAREs [14].
Effects of wild type α-synuclein in learning and memory
A popular area of study has been focused on the effects
of α-synuclein on cognition. Although α-Synuclein is a
mobile protein, it is primarily localized in axons and pre-
synaptic terminals of neurons in the brain regions that
are responsible for memory and emotions. A study was
done that examined the importance of α-Synuclein in cog-
nition using α-Synuclein knockout mice. Data from this
study revealed that the knockout mice had decreased
learning abilities in spatial and working memory, thereby
showing the significance of α-Synuclein in cognitive
processes [15]. Studies investigated the significance of
α-synuclein in spatial learning using the hidden platform
reference memory version of the water maze in α-
synuclein knockout mice. The α-synuclein knockout mice
showed no significant short-term learning impairments in
learning or probe trails compared with the wild type mice
reported from one study [16], while impairments in long
term spatial and working memory were observed in α-
synuclein knockout mice by another study, suggesting a
potential possibility that α-synuclein was necessary for
long-term memory specifically [15].
Role of α-synuclein aggregates in cognition
Morphogenesis of α-synuclein during neurodegeneration
α-Synuclein possesses a structural plasticity that is sig-
nificant to its involvement in neurodegenerative diseases.
In addition, defects in the structure of α-Synuclein, such as
misfolding, aggregation, and fibrillation factor into the on-
set of various neurodegenerative diseases. Many of the mu-
tations that are involved in the pathogenesis of PD have
been found to occur at the conserved amino-terminal
domain of α-Synuclein. When the unstable monomeric
α-Synuclein becomes disordered, it can form aggregates
that are rich in cross- β-structures. These structures con-
sist of long helical segments that bind to lipid vesicles
[17]. Furthermore, the intrinsically unstable α-Synuclein
monomer is dynamic, for it can take on a wide variety
of conformations, in which molecular crowding can
shift the equilibrium in favor of a folded state. There
are multiple site of α -synuclein that can be regulated
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α –synuclein alter its conformation, size, and charge,
which contributes to the progression of neurodegenerative
diseases. There is a wide variety of PTM alterations that
occur through numerous processes.
Pathogenesis of extracellular α-synuclein
It has been revealed that dopamine (DA) modulates α-
synuclein assembly by binding exclusively to the extended
conformation of α-synuclein [18]. It was concluded that
the loss of dopaminergic transporter in PD brain was a re-
sult of neuronal loss [19]. However, it remains unknown
whether the loss of DA transported is associated with
a-synuclein. Furthermore, another mechanism of α-
synuclein is its interaction with lipids, such as choles-
terol, which causes a conformational change of a-synuclein.
The conformed a-synuclein has a high affinity for choles-
terol, which creates a tilted geometry of the cholesterol/α-
synuclein complex. In turn, this complex facilitates the
formation of an oligomeric channel [3]. The aggregation
of α-synuclein oligomers is presumed to be detrimental to
cognitive function [20]. Studies show that prolonged ex-
posure to α-synuclein oligomers increases the basal synap-
tic transmission through the direct binding of α -synuclein
to the NMDA receptor activation site. This triggers the
firing of calcium-permeable AMPA receptors, which in-
hibits any response to physiological stimuli. Consequently,
this hinders learning and memory, because it impairs
long-term potentiation (LTP), which is a function that is
carried out in the hippocampus [21]. Recent findings have
shown a binding mechanism in which α-synuclein and Aβ
peptide directly interact together in a Lewy Body variant
of AD (LBV-AD) patients. It was shown that endogen-
ous α-synuclein or recombinant α-synuclein can protect
against soluble Aβ1-42 induced caspase-3-mediated cor-
tical neurons death via the PI3K/Akt cell survival pathway
[22,23]. A binding mechanism has been established in
which α-synuclein and Tau bind to DNA in a specific con-
formation that causes transformational transition and
stabilization of Z-DNA conformation [24,25]. Tau and α-
synuclein bind to the B-DNA conformation and alter its
form by increasing the melting temperature and decreas-
ing the EtBr molecules bound per base pair in the B form
of DNA. The altered B form is favored in DNA stability
and is a probable intermediate to form the favoring
Z-DNA conformation, which are inferred to have a sig-
nificant role in gene expression in neurodegeneration [26].
Furthermore, it was found that aggregated α-synuclein
can directly cross-seed tau fibrillization. Preformed α-
synuclein fibrils were assembled from recombinant pro-
tein in vitro (primary neurons) and in vivo (transgenic
mice). It was concluded that there were at least two dis-
tinct strains of synthetic α-synuclein fibrils with differ-
ences in the efficiency of cross-seeding tau fibrilization.Proteinase K digestion revealed variance in conformation
between these two synthetic strands of α-synuclein, sug-
gesting a potential distinct strain of α-synuclein likely exist
in neurodegenerative disease brains [27].
Synergistic extracellular and intracellular interactions of
α-synuclein on cognition
Past research has been done on solubility of α -synuclein
and its effect on cognition. Various immunoreactivities
were measured in the frontal cortex of elderly individ-
uals with no cognitive impairment (NCI), mild cognitive
impairment (MCI) and early AD subjects. In early AD
patients, α-synuclein solubility in the frontal cortex was
significantly lower than that in MCI and NCI individuals.
There were no differences in soluble α-synuclein levels
between MCI and NCI patients. It could be inferred
that a decrease in level of soluble α -synuclein may be an
early feature of cognitive decline in aging and AD [28].
The levels of mRNA and protein of soluble α -synuclein
have been measured in individuals with PDD, DLB, AD
and matched controls. It was found that levels of soluble
α-synuclein proteins were lower in DLB and PDD sub-
jects. There was no evidence for a corresponding decrease
in α-synuclein mRNA levels, which indicates that the al-
teration of soluble α -synuclein in PD and DLB is at pro-
tein level, not at the mRNA level [29]. In addition, a study
was done in which extracellular application of α-synuclein
oligomers was found to increase intracellular Ca2+ levels,
induce calcineurin activity, decrease cAMP response and
CREB transcriptional activity. This resulted in calcineurin-
dependent cell death of the human neuroblastoma cells.
Similarly, CaN induction and CREB inhibition were
observed when α-synuclein oligomers were applied to
organotypic brain slices, which opposed hippocampal
long-term potentiation. Furthermore, α-synuclein oligo-
mers induced CaN, inhibited CREB and caused memory
impairment in mice that received acute intracerebroven-
tricular injections of α-synuclein oligomers [30]. The gen-
eral mechanism of secretion of α-synuclein from the
intracellular complex to the extracellular complex is still
unknown. There are two pathways that are thought to be
involved in the secretion of α-synuclein by neurons. One
of them involves the non-classical calcium-dependent re-
lease of cytotoxic vesicular forms of α-synuclein from
transfected SH-SY5Y cells. The other pathway involves the
endoplasmatic reticulum/Golgi regulated exocytosis of
α-synuclein in primary enteric neurons dependent on
sodium channel depolarization of, α-synuclein and brefeldin-
A [31]. While the pathology of secreted α-synuclein remains
unknown, it appears that α-synuclein can be secreted from
neurons into the extracellular space, thereby affecting the
homeostasis of neighboring cells. This was demonstrated
in a study which found that COS-7 cells treated with ex-
ogenously applied α-synuclein secreted from differentiated
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endocytosis. Upon internalization, α-synuclein increased
in the rate of transferrin receptor (TfR) internalization and
recycling, a pathology presumed to be involved with PD
[32]. Compared to soluble Aβ and tau levels, the soluble
α-synuclein levels showed a stronger correlation to cog-
nitive impairment in AD [33]. It has been suggested
that cognitive dysfunction could be associated with the
misfolding of normal soluble α-synuclein by amyloid de-
position, suggesting the accumulation of amyloid and α-
synuclein caused the loss of solubility in the intracellular
cytosolic proteins [34].
α-Synuclein in neurodegenerative diseases
α-Synuclein and AD
Although studies have theorized a potential linkage be-
tween α-synuclein and its effects on cognition, the effect
of α-synuclein oligomer aggregation on cognition in AD
still requires further investigation. One recent study
examined the CSF levels of α-synuclein in MCI, AD
subjects and healthy controls and found that CSF α-
synuclein levels were significantly higher in the MCI and
AD groups compared to the control subjects, while the in-
creased α-synuclein levels were associated with decreased
Mini-Mental State Exam scores [8]. An interesting study
investigated the prevalence of Lewy Bodies (LBs) in AD by
using α-synuclein immunohistochemistry. It was found
that LBs were found in the amygdala of over 60% early on-
set AD; thus reducing the functioning of the amygdala in
emotional development and motivation, thereby impair-
ing cognitive ability of affected AD subjects [35]. Further-
more, there has been data that revealed an influence of
Alzheimer-related lesions on the progression of the neuro-
degenerative process, in particular, on cognitive decline
in both PDD and DLB. This data infers that there is
a possible synergistic reaction between α-synuclein, tau,
and amyloid beta-peptides, which are the major protein
markers of both AD and Lewy Body diseases, and of both
vascular pathology and AD [36].
Sariations of α-synuclein in AD and PD patients
The discrepancy of the role of α-synuclein in AD and PD
patients has been a popular research topic. The quantifica-
tion of α-synuclein in CSF has been used as a biomarker
to distinguish patients with AD, DLB, PD and Multiple
System Atrophy (MSA) [37]. For example, in comparison
with controls, CSF α-synuclein levels in AD were signifi-
cantly higher, while PD, DLB and MSA subjects showed
significantly lower levels of CSF α-synuclein than AD
patients, but they did not significantly differ from CSF
α-synuclein levels in the controls [38]. It was also reported
that α-synuclein expression was present in the enteric
neurons of patients with PD but not in AD patients. An
experiment was performed in which α-synuclein wasdetected in 52% of the general population and its level of
expression did not change between ages 40 and 91, while
all PD patients with α-synuclein positive and expressed
higher α-synuclein levels than that in the age-matched non-
PD controls, where AD subjects were no difference from
controls [39]. Thus, it can be concluded that either PD de-
velops selectively in the enterically α-synuclein positive sub-
set or PD induces this expression. The absence of increased
positive α-synuclein expression in AD subjects indicates that
there is a difference in pathogenesis between AD and PD.
There has been growing evidence of cell-to-cell transmission
of neurodegenerative disease-associated proteins, such as
α-synuclein, tau, and amyloid beta, which suggests similar-
ities to the infectious prion protein in spongiform ence-
phaloathies [40]. However, while there is little data on
potential human-human transmission of neurodegenera-
tive disease-associated proteins associated with AD, no
evidence shows α-synuclein as an infectious protein yet.
Future studies and current treatment options for
α-synuclein aggregation
There are various treatment approaches that prevent α-
synuclein aggregation and Lewy Body formation, such as
through gene therapy, immunochemistry, and reduction
of oxidative stress through diet. One treatment suggests
an alternative gene therapy, which requires the transfer of
genes that might block α-synuclein accumulation. The
β-synuclein, a non-amyloid homologue of α-synuclein,
has recently been identified as a potential inhibitor. The
in vivo transfer of β -synuclein provides a potential treat-
ment method for PD and DLB [2,41].
Treatment methods have been developed for neurode-
generative diseases such as PD and AD, which are
caused by aggregation of specific proteins. This method
entails that a patient with such neurodegenerative dis-
order receives a dose of a high affinity antibody fragment
that is immunoreactive with the protein that is aggre-
gated. In turn, this will halt the progression of the neu-
rodegenerative disease of the patient by inhibiting the
protein from aggregating [42]. A less conventional treat-
ment method for α-synuclein aggregation involves a
dietary treatment option. One study proposed that the
neuroprotective mechanism of the major green tea poly-
phenol, (−)-epigallocatechin-3-gallate can alter brain aging
processes and serve as possible neuroprotective agents in
progressive neurodegenerative disorders such as PD and
AD and assist in the cognitive decline of those who are
aging. The properties of green tea polyphenol hinders the
reactive oxygen species generation and inflammation of
neurodegenrative diseases [43]. There was a similar find-
ing concerning a therapeutic method that reduces oxida-
tive stress and free radical scavenger in neurodegenerative
diseases involving an antioxidant mechanism of antioxi-
dant action of lycopene [29].
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The associations of low CSF α-synuclein with poor cog-
nitive function have been used as hallmarks of neurode-
generative diseases, such as DLB, MCI and AD, partially.
Studies of animal models with genetic depletion of α-
synuclein showed decreased learning abilities in spatial and
working memory, suggested a potential possibility that α-
synuclein was necessary for non-disease related long-term
memory specifically. Together, all suggest that reduced α-
synuclein may reflect global impaired neuronal/synaptic
function, or non-specific overall cognitive deterioration.
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